UBS Knock-Out 1U1/ DE000UH4BH79 /
13.05.2024 19:38:15 | Изменение-0.090 | Бид13.05.2024 | Предложение13.05.2024 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
1.890EUR | -4.55% | 1.890 Величина цены спроса: 6,000 |
1.920 Величина цены предложения: 6,000 |
1+1 AG INH O.N. | 36.4591 EUR | 31.12.2078 | Put |
GlobeNewswire
6:00
SPEE3D LAUNCHES EXPEDITIONARY MANUFACTURING UNIT (EMU) – THE COMPLETE MOBILE ADDITIVE MANUFACTURING ...
GlobeNewswire
5:01
MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible S...
GlobeNewswire
4:10
Kilmer Sports Ventures Enters into Exclusive Negotiations to Acquire French Professional Football Cl...
GlobeNewswire
3:50
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3:00
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial Results on May 14, 2024
GlobeNewswire
3:00
GLOBAL LIFE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Bee...
GlobeNewswire
2:29
AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders...
GlobeNewswire
2:06
MBUU INVESTOR ALERT: Edelson Lechtzin LLP Urges Malibu Boats, Inc. (NASDAQ: MBUU) Shareholders With ...
GlobeNewswire
2:00
ROSEN, A LEADING LAW FIRM, Encourages Rivian Automotive, Inc. Investors With Losses in Excess of $10...
GlobeNewswire
2:00
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- an...
GlobeNewswire
2:00
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatme...
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница